Navigate to
-
Empowering client, providers and members Building a trusted, transparent PBM Tab 1 2021 – Current 2015 – 2020 2010 – 2014 1998 – 2009 Helping improve care, reducing cost through integration See our...
-
Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...
-
Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...
-
Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...
-
Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs
Prime Article: Stories -
-
Eyebrow High-Cost Therapy Profile: August 2024 Detailed information about intravenous (IV) linvoseltamab Oncology Linvoseltamab, intravenous (IV) Regeneron Pharmaceuticals Proposed indications...
-
Home Our solutions Modern technology MyRxInsights Our advanced analytics platform helps boost your clinical impact and drive down costs by delivering descriptive, diagnostic, predictive and...
-
When you fill your specialty prescription, we automatically enroll you in our Care Specialists program. Our care specialists are pharmacists and nurses who are specially trained in your condition....
-
Research awards AMCP Silver Award – Controlled Substances Triple Threat Overlapping Days: Relationship with Healthcare Utilization and Costs Academy of Managed Care Pharmacy: Annual Meeting AMCP...